open access

Vol 3, No 6 (2014)
Original articles (submitted)
Published online: 2015-01-20
Get Citation

Evaluation of the electrochemical skin conduction with the SUDOSCAN+ device in the diagnosis of diabetic neuropathy in patients with type 1 diabetes

Agnieszka Gandecka, Aleksandra Araszkiewicz, Dorota Zozulińska-Ziółkiewicz, Agata Grzelka, Bogna Wierusz-Wysocka
Diabetologia Kliniczna 2014;3(6):219-226.

open access

Vol 3, No 6 (2014)
Original articles (submitted)
Published online: 2015-01-20

Abstract

Introduction. Dysfunction of the sweat glands is an early clinical manifestation of diabetic neuropathy. SUDOSCAN+ is a device used to noninvasively assess the function of the sweat glands on the basis of the electrochemical reaction of chlorine ions secreted in sweat due to low voltage current. The aim of the study was to evaluate the electrochemical skin conductance with the device SUDOSCAN+ in the diagnosis of neuropathy in patients with type 1 diabetes.

Material and methods. The study included 203 patients with type 1 diabetes (95 women and 108 men) aged 39 years (IQR: 31–50), with disease duration of 22 years (IQR: 17–30) hospitalized in the Department of Internal Medicine and Diabetology, Poznan University of Medical Sciences, between years 2013–2014. The study group was subdivided into two groups depending on the presence of peripheral neuropathy identified by standard methods. In the study group we performed analysis of electrochemical skin conduction (ESC) measured with SUDOSCAN+ on the hands and feet with estimation of Risk of Autonomic Neuropathy. We also evaluated the accumulation of advanced glycation end products in the skin on the basis of the autofluorescence skin ratio (AGE Reader device).

Results. We diagnosed peripheral neuropathy in 45.3% of patients. Patients with peripheral neuropathy, compared to those without clinical neuropathy, had lower Feet ESC [70.5 (IQR: 51.5–83) vs. 83 μS (IQR: 78–87), p < 0.001], Hands ESC [58.5 (IQR: 47.5–71.5) vs. 70 μS (IQR: 61–78), p < 0.001] and a higher Risk of Autono­mic Neuropathy [24.5 (IQR: 13–35) vs. 11% (IQR: 1–20), p < 0.001]. We found a negative correlation between the result of the Feet ESC and patients age (Rs = –0.40, p < 0.001), duration of diabetes (Rs = –0.32, p < 0.001), skin autofluorescence (Rs = –0.38, p < 0.001) and positive correlation with the eGFR (Rs = 0.32, p < 0.001).

Conclusions. Electrochemical skin conductance is reduced in patients with type 1 diabetes and diabetic neuropathy. Sudomotor dysfunction is related to longer duration of diabetes, chronic metabolic uncontrolled diabetes, and worse renal function.

Abstract

Introduction. Dysfunction of the sweat glands is an early clinical manifestation of diabetic neuropathy. SUDOSCAN+ is a device used to noninvasively assess the function of the sweat glands on the basis of the electrochemical reaction of chlorine ions secreted in sweat due to low voltage current. The aim of the study was to evaluate the electrochemical skin conductance with the device SUDOSCAN+ in the diagnosis of neuropathy in patients with type 1 diabetes.

Material and methods. The study included 203 patients with type 1 diabetes (95 women and 108 men) aged 39 years (IQR: 31–50), with disease duration of 22 years (IQR: 17–30) hospitalized in the Department of Internal Medicine and Diabetology, Poznan University of Medical Sciences, between years 2013–2014. The study group was subdivided into two groups depending on the presence of peripheral neuropathy identified by standard methods. In the study group we performed analysis of electrochemical skin conduction (ESC) measured with SUDOSCAN+ on the hands and feet with estimation of Risk of Autonomic Neuropathy. We also evaluated the accumulation of advanced glycation end products in the skin on the basis of the autofluorescence skin ratio (AGE Reader device).

Results. We diagnosed peripheral neuropathy in 45.3% of patients. Patients with peripheral neuropathy, compared to those without clinical neuropathy, had lower Feet ESC [70.5 (IQR: 51.5–83) vs. 83 μS (IQR: 78–87), p < 0.001], Hands ESC [58.5 (IQR: 47.5–71.5) vs. 70 μS (IQR: 61–78), p < 0.001] and a higher Risk of Autono­mic Neuropathy [24.5 (IQR: 13–35) vs. 11% (IQR: 1–20), p < 0.001]. We found a negative correlation between the result of the Feet ESC and patients age (Rs = –0.40, p < 0.001), duration of diabetes (Rs = –0.32, p < 0.001), skin autofluorescence (Rs = –0.38, p < 0.001) and positive correlation with the eGFR (Rs = 0.32, p < 0.001).

Conclusions. Electrochemical skin conductance is reduced in patients with type 1 diabetes and diabetic neuropathy. Sudomotor dysfunction is related to longer duration of diabetes, chronic metabolic uncontrolled diabetes, and worse renal function.

Get Citation

Keywords

diabetic neuropathy, type 1 diabetes mellitus, electrochemical skin conductance, small fiber neuropathy

About this article
Title

Evaluation of the electrochemical skin conduction with the SUDOSCAN+ device in the diagnosis of diabetic neuropathy in patients with type 1 diabetes

Journal

Clinical Diabetology

Issue

Vol 3, No 6 (2014)

Pages

219-226

Published online

2015-01-20

Bibliographic record

Diabetologia Kliniczna 2014;3(6):219-226.

Keywords

diabetic neuropathy
type 1 diabetes mellitus
electrochemical skin conductance
small fiber neuropathy

Authors

Agnieszka Gandecka
Aleksandra Araszkiewicz
Dorota Zozulińska-Ziółkiewicz
Agata Grzelka
Bogna Wierusz-Wysocka

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Diabetologia Kliniczna dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl